These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8152428)

  • 1. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions.
    Tzukerman MT; Esty A; Santiso-Mere D; Danielian P; Parker MG; Stein RB; Pike JW; McDonnell DP
    Mol Endocrinol; 1994 Jan; 8(1):21-30. PubMed ID: 8152428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular mechanisms which distinguish between hormone- and antihormone-activated estrogen receptor.
    McDonnell DP; Dana SL; Hoener PA; Lieberman BA; Imhof MO; Stein RB
    Ann N Y Acad Sci; 1995 Jun; 761():121-37. PubMed ID: 7625716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity.
    Fan JD; Wagner BL; McDonnell DP
    Mol Endocrinol; 1996 Dec; 10(12):1605-16. PubMed ID: 8961270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.
    Hall JM; McDonnell DP
    Endocrinology; 1999 Dec; 140(12):5566-78. PubMed ID: 10579320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists.
    Montano MM; Müller V; Trobaugh A; Katzenellenbogen BS
    Mol Endocrinol; 1995 Jul; 9(7):814-25. PubMed ID: 7476965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens.
    McDonnell DP; Clemm DL; Hermann T; Goldman ME; Pike JW
    Mol Endocrinol; 1995 Jun; 9(6):659-69. PubMed ID: 8592512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor.
    Zhang X; Jeyakumar M; Petukhov S; Bagchi MK
    Mol Endocrinol; 1998 Apr; 12(4):513-24. PubMed ID: 9544987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens.
    Webb P; Lopez GN; Uht RM; Kushner PJ
    Mol Endocrinol; 1995 Apr; 9(4):443-56. PubMed ID: 7659088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-alpha 1 promoter via a novel sequence.
    Elgort MG; Zou A; Marschke KB; Allegretto EA
    Mol Endocrinol; 1996 May; 10(5):477-87. PubMed ID: 8732679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of transcriptionally inactive human estrogen receptors by cyclic adenosine 3',5'-monophosphate and ligands including antiestrogens.
    Ince BA; Montano MM; Katzenellenbogen BS
    Mol Endocrinol; 1994 Oct; 8(10):1397-406. PubMed ID: 7531820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting.
    Kelley KM; Rowan BG; Ratnam M
    Cancer Res; 2003 Jun; 63(11):2820-8. PubMed ID: 12782587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta.
    Watanabe T; Inoue S; Ogawa S; Ishii Y; Hiroi H; Ikeda K; Orimo A; Muramatsu M
    Biochem Biophys Res Commun; 1997 Jul; 236(1):140-5. PubMed ID: 9223441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-hydroxytamoxifen trans-represses nuclear factor-kappa B activity in human osteoblastic U2-OS cells through estrogen receptor (ER)alpha, and not through ER beta.
    Quaedackers ME; Van Den Brink CE; Wissink S; Schreurs RH; Gustafsson JA; Van Der Saag PT; Van Der Burg BB
    Endocrinology; 2001 Mar; 142(3):1156-66. PubMed ID: 11181531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha.
    Gougelet A; Mueller SO; Korach KS; Renoir JM
    J Steroid Biochem Mol Biol; 2007 May; 104(3-5):110-22. PubMed ID: 17478088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional synergy between the transcription factor Sp1 and the estrogen receptor.
    Porter W; Saville B; Hoivik D; Safe S
    Mol Endocrinol; 1997 Oct; 11(11):1569-80. PubMed ID: 9328340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes.
    Lazennec G; Ediger TR; Petz LN; Nardulli AM; Katzenellenbogen BS
    Mol Endocrinol; 1997 Aug; 11(9):1375-86. PubMed ID: 9259327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo.
    Metzger D; Berry M; Ali S; Chambon P
    Mol Endocrinol; 1995 May; 9(5):579-91. PubMed ID: 7565805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A transcriptionally active estrogen receptor mutant is a novel type of dominant negative inhibitor of estrogen action.
    McInerney EM; Ince BA; Shapiro DJ; Katzenellenbogen BS
    Mol Endocrinol; 1996 Dec; 10(12):1519-26. PubMed ID: 8961262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiestrogens: mechanisms and actions in target cells.
    Katzenellenbogen BS; Montano MM; Le Goff P; Schodin DJ; Kraus WL; Bhardwaj B; Fujimoto N
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):387-93. PubMed ID: 7626486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.